Jonathan S. Serody MD
Curriculum Vitae
Departments of Medicine, Microbiology and Immunology
Lineberger Comprehensive Cancer Center
450 West Drive
Campus Box #7295
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599-7295
Phone: 919 966-6975
FAX: 919 966-8212
e-mail: jonathan_serody@med.unc.edu
Address of Clinical Investigation:
UNC Hospitals
The University of North Carolina at Chapel Hill
101 Manning Drive
Chapel Hill, NC 27599-7600
Education:
Postdoctoral Fellowship
Department of Microbiology and Immunology, University of
North Carolina at Chapel Hill; mentor Jeffrey Frelinger PhD, 1990-1993
Fellowship in Clinical Bone
Marrow Transplantation:
Fred Hutchinson Cancer Research Center, 1993
Fellowship in Hematology: North Carolina Memorial Hospital, July 1990-Jan 1993
Fellowship Infectious
Diseases:
North Carolina Memorial Hosp, July 1989-July 1992
Residency in Medicine:
North Carolina Memorial Hospital, July 1987-July 1989
Internship in Medicine:
North Carolina Memorial Hospital, July 1986-July 1987
Doctor of Medicine
University of Virginia Med School, July 1982-June 1986
Bachelor of Arts in Biology University of Virginia, July 1978-June 1982
Review Groups, Honors and Awards:
1987: Outstanding Intern University of North Carolina Hospitals
1992: National Research Service Award NIH
1996: KO8 Grant National Cancer Institute
1997: Ad Hoc Member Food and Drug Administration's Fever and Neutropenia Committee
1997-01: Ad Hoc Member National Cancer Institute Scientific Review Group Subcommittee D
1
2000-2002: Ad Hoc Member Parent Committee National Cancer Institute Scientific Review
Group Subcommittee D
2001: Member Review Committee SPORE in Gyn Cancer Study Section
2001-2004: Scientific Subcommittee on Transplantation Biology American Society of
Hematology
2002: Member Review Committee SPORE in Ovarian Cancer Study Section
2003: Member Review Committee SPORE in Leukemia/Lymphoma
2003: Presentation on Update in GVHD Biology American Society of Hematology Meeting
2003: Ad hoc Member Immunotherapy-Gene Therapy P01 Cluster Review NCI
2004-2007: Member SPORE Parent Committee
2005, 2006: Ad hoc Member CONC Study Section
2005: Ad hoc Member TTT Study Section
2005: Grant Review Wellcome Trust UK
2005-2012: Standing member Leukemia and Lymphoma Society TRP Grant Review
2005-present: co-leader Immunology Program Lineberger Comprehensive Cancer Center
2006: Named Elizabeth Thomas Associate Professor of Medicine, Microbiology and
Immunology
2005-2012: Castle Connolly America’s Top Doctors in Cancer
2006-2012 Castle Connolly America’s Top Doctors
2006-2012: Member LRP Study Section
2007-2010: Standing Member TTT Study Section
2007-2009: Interim leader Malignant Hematology Program Lineberger Comprehensive Cancer
Center
2008-present: External Advisory Board Johns Hopkins School of Medicine Breast Cancer
Program
2008-2013: Scientific Subcommittee Lymphocyte Biology and Host Defense American Society
of Hematology
2008-present: Hematology and Oncology Division Research Coordinator
2009-2012: CIBMTR Scientific Committee on Immunosurveillance
2010-present: Leader Malignant Hematology Program Lineberger Comprehensive Cancer Center
2010-2012: External Advisory Board Duke University Medical School Lymphoma Program
2010-present: Section Chief: Leukemia, Lymphoma and Myeloma Program Division of Medical
Oncology
2010: CCSG Review Group University of Maryland Cancer Center
2011: Presidential Symposium Address American Association for Immunology
2011: ASH Basic Science Scholar Grant Review Group
2012: Chair SEP for RFA Review for NHLBI RFA “Early Phase Clinical Trials for Blood
Therapies.”
2012: Invited Talk ASBMT meeting “Th17/Th22 Cells Key Actors or Bit Players in Acute
GvHD.”
2012: Reviewer for NHLBI SEP ZRG1-OTC-C: SEP for TTT Members
2012: ASH Basic Science Scholar Grant Review Group
Employment History:
December 2010-present
Leader Malignant Hematology Program Lineberger Cancer Center
August 2010-present
Section Chief Leukemia, Lymphoma and Myeloma Service
Division of Medical Oncology the University of North Carolina at
2
July 2008-present
November 2006
July 2000
July 1998
July 1993 – July 2000:
Chapel Hill, NC
Elizabeth Thomas Professor of Medicine, Microbiology and
Immunology, The University of North Carolina at Chapel Hill,
NC.
Elizabeth Thomas Endowed Associate Professor of Medicine,
Microbiology and Immunology
Associate Professor of Medicine, The University of North Carolina
at Chapel Hill, NC
Joint Appointment in Microbiology and Immunology The
University of North Carolina at Chapel Hill
Assistant Professor of Medicine, The University of North Carolina
at Chapel Hill, NC
Bibliography
Peer Reviewed
1. Lin K, Coghill JM, West ML, Dustin M, Bear JM, Serody JS. Intravital imaging reveals
multiple mechanisms for regulatory T cell function during GVHD. Nature Medicine
(under review).
2. Dharmasiri U, Vincent, BV, , Hunsucker SA, Alatrash G, Sarantopoulos S, Serody JS,
Molldrem JJ, Armistead PM. Use of RNA sequencing to identify antigens from RNA
spliced variants from leukemia stem cell blasts. Science Translational Medicine (under
review).
3. Fulton LM, West ML, Coghill JM, Panoskaltsis-Mortari A, Bear JM, Foger N, Serody
JS. Absence of Coronin 1A markedly attenuates GVHD by preventing lymphocyte
migration and egress from secondary lymphoid tissue. Blood (under review).
4. Coghill JM, Fowler K, West ML, Bear J, Panoskaltsis-Mortari A, Power C, Serody JS.
APC interaction via CCR8 is required for the longitudinal persistence of regulatory T
cells after stem cell transplantation. Blood (under revision).
5. Wu QP, Serody JS, Van Deventer HW. Fibrocytes are critical to the recruitment of
CD11b+ myeloid cells and the promotion of lung metastases. PLoS Biology (under
review)
6. Mango RL, Wu QP, West ML, Davis BK, Serody JS, van Deventer HW. CC-Chemokine
Receptor 5 on Pulmonary Mesenchymal Cells Promotes Metastasis through Induction of
Erythroid Differentiation Regulator 1. Clinical and Experimental Metastasis (submitted).
7. Allen, JL, Fore MS, Wooten J, Roerhs PA, Nazmim BS, Hoffert T, Sharf A, Deal A,
Armistead PM, Coghill JM, Gabriel D, Irons RN, Essenmacher A, Shea TC, Richards
KL, Cutler C, Ritz J, Serody JS, Baldwin AS Jr. B cells from patients with chronic
3
GVHD are activated and primed for survival via BAFF mediated pathways. Blood. 2012
Aug 14 [Epub ahead of print]
8. Fedoriw Y, Samulski TD, Deal AM, Dunphy CH, Sharf A, Shea TC, Serody JS.
Sarantopoulos S. Bone marrow B cell precursor number after allogeneic stem cell
transplantation and GVHD development. Biology of Blood and Marrow Transplantation.
18(6): 968-973, 2012.
9. Fulton, LM, Carlson MJ, Coghill JM, Ott LE, West ML, Panoskaltsis-Mortari A, Littman
DR, Blazar BR, Serody JS. Critical role for RORt expression by CD4+ T cells in GvHD
mediated by CD8+ T cells. The Journal Immunology 189(4) 1765-1772, 2012.
10. Wood, W, Deal A, Whitley J, Sharf A, Serody J, Gabriel D, Shea T. Usefulness of the
hematopoietic cell transplantation-specific comorbidity index (HCT-IC) in predicting
outcomes for adolescents and young adults with hematologic malignancies undergoing
allogeneic stem cell transplant. Pediatric Blood Cancer 2011 Mar 7 doi 10,
1002/pbc23057 epub ahead of print.
11. Beaven AW, Moore DT, Sharf A, Serody JS, Shea TC, Gabriel DA. Infusional
mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for
multiple myeloma. Cancer Investigations. 29(3): 214-219, 2011.
12. Coghill, JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector
CD4+ T cells, the cytokines they generate and graft-versus-host disease: Something Old,
Something New. Blood . 2011 Jan 18 [Epub ahead of print].
13. Highfill SL, Rodriguez PC, Zhou Z, Goetz CA, Koehn BH, Veenstra RG, Taylor PA,
Panoskaltsis-Mortari A, Serody JS, Munn DH, Tolar J, Ochoa AC, Blazar BR. Bone
marrow myeloid-derived suppressor cells (MDSC) inhibit graft-versus-host disease
(GVHD) via an arginase-1 dependent mechanism that is upregulated by IL-13. Blood
116(25): 5738-5747, 2010.
14. Carlson M, Fulton, L, Coghill JM, West MJ, Panoskaltsis-Mortari, A, Wan Y, Tedder T,
Blazar BR, Serody JS. L-selectin is not absolutely required for regulatory T cell function
in GVHD. American Journal of Transplantation, 10(12): 2596-2603, 2010.
15. *Van Deventer H, *Burgents JE, Wu QP, Woodford RM, Brickey WJ, Allen IC, Tekippe
EM, **Serody JS, **Ting JPY. The inflammasome component, NLRP3, impairs
antitumor vaccination by enhancing accumulation of peritumoral myeloid derived
suppressor cells. Cancer Research. 70(24): 10161-10169, 2010.* and ** equally
contributed to work
16. Wood WA, Whitley J, Moore D, Sharf A, Iron R, Rao K, Serody J, Gabriel D, Shea T.
Chemomobilization with etoposide is highly effective in patients with myeloma and
overcomes the effects of age and prior therapy. Biology of Blood and Marrow
Transplantation. 17(1): 141-146, 2011.
4
17. Coghill JM, Carlson MJ, Panoskaltsis-Mortari A, West ML, Burgents JE, Blazar BR,
Serody JS. Separation of graft-versus-host disease from graft-versus-leukemia responses
by targeting C-C chemokine receptor 7 on donor T cells. Blood 115(23): 4914-4922,
2010 (Inside Blood Comment).
18. Burgents, JE, Moran TM, Collier ML, West MJ, Davis NL, Johnston RE, Serody JS. The
immunosuppressive tumor environment is the main impediment to successful vaccination
in neu transgenic mice. J Immunotherapy 33(5): 482-491, 2010.
19. Wood, W, Garg, S, Adamus G, Gabriel D, Shea T, Serody, J. Alloimmune Retinopathy
associated with antibodies to transducin-α as a complication of chronic GVHD. Biol of
Blood and Marrow Transplantation DOI: 10:1016/j 06.012, 2009..
20. Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao NK, Gockerman J,
Lindley C, Garcia R, Schell M and Rizzieri DA.Sequential high-dose ifosfamide,
carboplastin and etoposide with ritucimab for relapsed Hodgkin and large B-cell nonHodgkin lymphoma: increased toxicity without improvement in progression-free
survival. Leukemia & Lymphoma 8(1-8) (epub ahead of print, 2009).
21. Rao, KV, Buie LW, Shea T, Gabriel DA, Comeau T, Irons R, Serody J, Eron B.
Intravesicular cidofovir for the management of BK virus-associated cystitis. Biol Blood
Marrow Transplant 15(3): 391-392, 2009.
22. O’Shaunessey MJ, Vogtenhuber C, Sun K, Sitcheran R, Baldwin AS, Murphy WJ, Dang
L, Jaffee B, Palmer E, Serody JS, Blazar BR..Ex vivo inhibition of NF-kappaB signaling
in alloreactive T-cells prevents graft-versus-host disease. American Journal of
Transplantation 9(3): 452-462, 2009.
23. Carlson, MJ, West M, Panoskaltsis-Mortari, A, Blazar BR. Serody JS. In vivo generated
Th17 cells mediate lethal GVHD with severe cutaneous and pulmonary pathology.
Blood113(6): 1365-1374, 2009.
24. Taylor PA, Ehrhardt MJ, Lees CJ, Panoskaltsis-Mortari A, Krieg AM, Sharpe AH,
Murphy WJ, Serody JS, Hemmi H, Akira S, Levy RB, Blazar BR. TLR agonists regulate
alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow
rejection. Blood 112(8): 3508-3516, 2008.
25. Coghill, J, Carlson M, Moran TJ and Serody JS. The biology and therapeutic potential of
natural regulatory T-cells in the bone marrow transplant setting. Leukemia and
Lymphoma July 25, 1-10, 2008.
26. van Deventer HW, Ping QW, Bergstralh DT, Davis BK, O'Connor BP, Ting JPY and
Serody JS. C-C Chemokine Receptor 5 on Pulmonary Fibrocytes Facilitates Migration
and Promotes Metastasis via Matrix Metalloproteinase 9. American Journal of Pathology,
173(1): 253-264, 2008.
5
27. Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon KP, Buehler C, Kim W,
Shields JM, Bear JE, Thomas NE, Serody JS, Sharpless NE. Erk activation induces
CD200 expression and T cell suppression in melanoma. Journal of Clinical Investigation
117(12): 3922-3929, 2007.
28. Moran TP, Burgents JE, Long B, Ferrer I, Jaffee EM, Tisch R, Johnston RE, Serody JS.
Alphaviral-vector transduced dendritic cells are successful therapeutic vaccines against
Neu-expressing tumors. Vaccine 25(36):6604-6612, 2007.
29. Taylor PA, Ehrhardt MJ, Lees CJ, Tolar J, Weigel BJ, Panoskaltsis-Mortari A, Serody
JS, Binkmann V, Blazar BR. Insights into the mechanism of FTY720 and compatibility
with regulatory T cells for the inhibition of GVHD. Blood 110(9): 3480-3488, 2007
30. Serody J. The CCR deletion mutation and graft-versus-host disease. Haematologica.
91(12): 1586A, 2006
31. Taylor PA Ehrhardt MJ, Roforth MM, Swedin JM, Panoskaltsis-Mortari A, Serody JS,
Blazar BR. Preformed antibody, not primed T cells, is the initial and major barrier to
bone amrrow engraftment in allosensitized recipients. Blood 109(3): 1307-1315, 2007.
32. Gilman A and Serody JS. Biology and Management of chronic GVHD. Seminars in
Hematology 43(1): 70-80, 2006.
33. Gabriel DA, Shea TC, Serody JS, Moore, DT, Kirby SL, Harvey, D, Bigelow SH, and
Krasnov C. Cytoprotection by Amifostine (Ethyol®) During Autologous Stem Cell
Transplantation for Advanced Refractory Hematologic Malignancies. Biology of Blood
and Marrow Transplantation 11(12): 1022-1030, 2005.
34. Taylor, PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe, AH, Noelle RJ, Rudensky AY,
Mak TW, Serody JS, Blazar BR. Targeting of inducible costimulator expressed on
alloreactive T cells down regulates graft-versus-host disease and facilitates engraftment
of allogeneic bone marrow. Blood. 105(8): 3372-3380, 2005.
35. Moran, T, Collier, M, McKinnon, KP, Davis NL, Johnston RE, Serody JS. A novel viral
system for generating antigen-specific T cells. Journal of Immunology. 175(3): 34313438, 2005.
36. Wysocki, C, Panoskaltisis-Mortari, A, Blazar BR, Serody JS. Leukocyte migration and
GVHD. Blood. 105(11): 4191-4199, 2005.
37. Wysocki C, McKinnon KM, Raimondo C, Lee H, Su, L, Blazar BR, Serody JS. Critical
role for CCR5 in the function of CD4CD25+ regulatory T cells during acute GVHD.
Blood 2005 July 7 106(9): 3300-3307, 2005.
6
38. van Deventer H, O’Connor Jr W, Brickey WJ, Aris RM, Ting JPY, Serody JS. Critical
role for stromal cell production of CCR5 in pulmonary metastasis. Cancer Research 65:
3374-3379, 2005.
39. Hildebrandt, GC, Olkiewicz, KM, Choi S, Corrion LA, Clouthier S, Liu C, Serody JS,
and Cooke KR. Donor T cell production of RANTES significantly contributes to the
development of idiopathic pneumonia syndrome after allogeneic stem cell
transplantation. Blood. 105:3372-3380, 2005. (Plenary Manuscript)
40. Blazar BR, Levy RB, Mak TW, Mortari-Panoskaltsis A, Muta, H, Jones, M, Roskos, M,
Serody JS, Yagita, H, Podack ER, and Taylor PA. CD30/CD30 ligand (CD153)
interaction regulates CD4+ T cell mediated graft-versus-host disease. Journal of
Immunology. 173:2933-2941, 2004.
41. Taylor, P, Panoskaltsis-Mortari, A, Wilson, J, Lucas, P, Gress, R, Levine, B, June, C,
Serody JS, Blazar, BR. L-selectin but not the L-selectin lo CD4+25+ T-regulatory cells
are potent inhibitors of GVHD and BM graft rejection. Blood 104, 3804-12, 2004.
42. Sun, K, Welniak LA, Panoskaltsis-Mortari, A, O’Shaughnessy, MJ, Liu, H, Barro I,
Riordan, W, Sticheran R, Wysocki C, Serody JS, Blazar BR, Sayers, TJ, and Murphy
WJ. Inhibition of acute GVHD with promotion of anti-tumor effects by the proteasome
inhibitor, bortezemib, after allogeneic bone marrow transplantation. Proceedings of the
National Academy of Science USA. 101(21): 8120-8125, 2004.
43. Sauer MG, Ericson ME, Weigel BJ, Herron MJ, Panoskaltsis-Mortari A, Kren BT,
Levine BL, Serody JS, June CH, Taylor PA, Blazar BR. A novel system for
simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo
generated leukemia-reactive cytotoxic T cells. Cancer Research 64(11): 3914-3921, 2004
44. Wysocki, C, Burkett SE, McKinnon, K Kirby, SL, Luster, A, Blazar BR and Serody JS.
Differential role of CCR5 on donor T cells during GVHD based on pretransplant
conditioning. Journal of Immunology 173(2)845-854, 2004
45. Dees, EC, McKinnon,van Deventer H, Chwastiak K, Sparks, S, Myers, M, Collins, E,
Frelinger J, Collichio, F, Carey, L, Brecher, M, Earp, HS, Graham, M, and Serody JS.
Dendritic cells can be rapidly and effectively expanded in patients with metastatic breast
cancer. Cancer Immunology Immunotherapy. 53(9): 777-785, 2004.
46. Panoskaltsis-Mortari, A, Price, A, Hermanson, J, Taras, E, Lees, E, Serody JS, Blazar,
BR. In vivo imaging of graft-versus-host disease in mice. Blood 103:3590-3598, 2004.
47. Shea, TC, Brunner, R, Wiley, JM, Serody JS, Sailer, S, Gabriel DA, Capel E, Moore, D,
Dent, G, Bentley, S and Brecher, M. An Expanded Phase I Trial of Cyclophosphamide,
Etoposide, and Carboplatin plus Total Body Irradiation with Autologous Marrow or Stem
Cell Support for Patients with Hematologic Malignancies. Biology of Blood and Marrow
Transplantation 9(7):443-452, 2003.
7
48. Lindley, C, McCune, JS, Shord, S, Decker, J., Harvey, D., Kirby, SL, Gabriel DA, Petros,
WP, Shea TC, Serody JS, and Wiley JM. Intraindividual variability in busulfan
pharmacokinetics in patients undergoing a bone marrow transplant: Assessment of a test
dose and first dose strategy. Anti-Cancer Drugs. 15(5): 453-459, 2004.
49. Mortari-Panoskaltsis, A, Hermansen, JR, Taras, E, Wangensteen OD, Serody JS, and
Blazar BR. Acceleration of idiopathic pneumonia syndrome (IPS) in the absence of donor
MIP-1 (CCL3) after allogeneic BMT in mice. Blood. 101: 3714-21, 2003.
50. van Deventer, Serody, JS, McKinnon, KP, Clements, C, Brickey, WJ, Ting JPY.
Transfection of Macrophage inflammatory protein 1a into B16-F10 melanoma cells
inhibits growth of pulmonary metastases but not subcutaneous tumors. Journal of
Immunology 169:1634-1639, 2002.
51. Ng-Cashin, J, Kuhns, JJ, Burkett, S.E., Powderly, JD, Craven, RR, van Deventer, HW,
Kirby, SL and Serody JS. Host absence of CCR5 potentiates DC vaccination. Journal of
Immunology. 170: 4201-08, 2003.
52. Serody JS, Burkett S, Mortari-Panoskaltsis A., Ng-Cashin J, McMahon E., Matshushima
G, Lira SA, Cook DN, Blazar BR. T lymphocyte production of MIP-1( is critical to the
recruitment of CD8+ T cells to the liver, lung and spleen during graft-versus-host disease.
Blood. 96: 2973, 2000.
53. Serody, JS. Sparks, S Yin, Y., Capel E., Bigelow, S. Kirby, SL. Gabriel, D. Wiley, JM.,
Brecher, M., Schell, M., Folds, F. and Shea, TC. Comparison of g-CSF-mobilized
peripheral blood progenitor cells and g-CSF-stimulated bone marrow as a source of stem
cells in HLA-matched sibling transplantation. Biology of Blood and Marrow
Transplantation. 6:434-440, 2000
54. Serody JS, Berrey MM, Albritton K, Schell M, O'Brien S, Weber DJ, Powell E, Gabriel
DA, Wiley JH, Gilligan P, Shea TC. Utility of obtaining blood cultures during febrile
leukopenia in bone marrow transplant recipients. Bone Marrow Transplantation. 26(5):
533-39, 2000.
55. Serody JS, Collins EJ, Tisch R, Kuhns JJ, Frelinger JA. Dendritic cell vaccination is
dependent on the antigen and route and frequency of administration. Journal of
Immunology 164:4961-4967, 2000
56. Cook D. N., O Smithies, RM Strieter, JA Frelinger, and JS Serody. CD8+ T cells are in
vivo relevant source of MIP-1a. Journal of Immunology 162:5423-5428, 1999.
57. Serody JS, Cook DN, Kirby SL, Reap E., Shea TC, and Frelinger JA. Murine T
lymphocytes incapable of producing MIP-1( are impaired in causing GVHD across a
class I but not class II MHC barrier. Blood 93:43-50, 1999.
8
58. Serody JS, Brecher ME, Dent G, Bentley SA, Frelinger JA, Shea TC. A method for the
production of CD4 positive CML-specific allogeneic T lymphocytes, Cancer Research
57:1547-1553, 1997.
59. Bentley SA, Brecher ME, Powell E, Serody JS, Wiley JM, Shea TC. Late engraftment
failure after Marrow ablation and autologous hematopoietic reconstitution: Differences
between peripheral blood stem cell and bone marrow recipients. Bone Marrow
Transplantation, 19:(6), 557-563 1997.
60. Serody J, Poston RM, Weinstock D, Kurlander RJ, Frelinger JA. CD4+ cytolytic
effectors are inefficient in the clearance of Listeria monocytogenes. Immunology 88:544550, 1996.
61. Bandarenko NB, Brecher ME, Owen H, Wiley J, Shea T, Serody J. Thrombocytopenia
in allogeneic peripheral blood stem cell collections. Transfusion, 36:7, p 668-669, 1996.
62. Rex JH, Benrett JE, Sugar AM, Pappas PG, Serody JS, Edwards, JED, and Washburn
RG. Intravascular catheter exchanges and the duration of candidemia. Clinical Infectious
Disease. 21:994-6, 1995.
63. Britigan BE, Serody JS, Rosen GM and Cohen MS. Lactoferrin, as an anti inflammatory
protein in professional phagocytic cells. Advances in Experimental Medicine & Biology.
357: 143-156, 1994.
64. Serody JS, Mill MR, Detterbeck FC, Harris DT and Cohen MS. Blastomycosis in
transplant patents: Report of a case and review of the literature. Clinical Infectious
Disease. 16(1):54-8, 1993.
65. Cohen MS, Mao J, Rasmussen GH, Serody JS and Britigan BE. Interaction of
lactoferrin and lipopolysaccharide: Effects of lactoferrin antioxidant activity and priming
of human neutrophils for formation of OH. Journal of Infectious Disease. 166(6):1375-9,
1992
66. Britigan BE, Serody JS, Hayek MB, Charniga LM and Cohen MS. Receptor-mediated
uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl
radical. Journal of Immunology 147:4271-4277, 1991.
Non Peer Reviewed Manuscripts:
1. Serody JS. Bacterial sepsis and GI tract GVHD: More commensal than you think. Blood
120(1): 6-7, 2012.
2. Serody JS, Hill GR. The IL-17 differentiation pathway and its role in transplant outcome.
Biology of Blood and Marrow Transplantation. 1 Suppl) S56-61, 2012
3. Serody JS. Recertification, the good, the bad and the ugly. The Hematologist, May 2007.
9
4. Gabriel DA, Shea, T, Olajiida, O, Serody, JS, Comeau, T. The effect of oral mucositis on
morbidity and mortality in bone marrow transplant. Semin Oncol 6 (Suppl 18): 76-83,
2003.
5. Shea, TS, Serody JS, Gabriel, DG, Bigelow, S, Capel E, Brecher, ME, Kirby, SL.
Cytokine-stimulated bone marrow for allogeneic transplantation. Cancer Research Therapy
and Control 2001.
6. Frelinger JA, and Serody JS. Immune response of beta 2-microglobulin-deficient mice to
pathogens. Current Topics in Microbiology and Immunology. 232:99-114, 1998
7. Serody JS, Shea TC. Prevention of infections in bone marrow transplant recipients.
Infectious Disease Clinics of North America, Vol 11, No 2, June 1997, 459-477.
8. Shea T, Graham M, Bernard S, Steagall A, Wiley J, Serody J, Brecher M, Bentley S,
Johnston C, Vaisman A, Chaney S, Letrent S, Brouwer K. A clinical and pharmacokinetic
study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and
peripheral blood stem cells in patients with unresectable or metastatic cancer. Sem in
Oncology 22:4(M), p 85-90, 1995
Book Chapters
Cooke K, Coghill, J, Hildebrand G and Serody JS. Chemokines in the biology of GvHD and the
GvL response. Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation. Editors
Bruce Blazar and Gerald Socie, Elsevier Publishing (due December 2012).
Blazar BR, Moran T, Serody JS. Th17 cells in GVHD. Th17 book, Springer Publishing New
York May 2011.
Peppercorn A and Serody JS. Fungal infections. Netter’s Internal Medicine
Murphy, W, Serody JS and Cooke, K. Chemokine and Chemokine receptors in GVHD. Graftversus-host disease, Marcel Dekker Inc, 2004.
Serody JS and Frelinger JA. Immune Response of beta 2 microglobulin-deficient mice to
pathogens in Antigen Presentation. Springer Verlag, 1998. pp 99-115
Serody JS , Kelly M, and Cohen MS. Infections of immunocompromised hosts in Infectious
Disease in Emergency Medicine, Lippincott, 1997. pp372-400.
Serody JS and van der Horst CM. The Control of CMV Infection in Molecular Aspects of
Human Cytomegalovirus Dieseases (Frontiers in Virology 2). Springer Verlag, 1993. pp 257-282
Serody JS and Cohen MS. Infections of immunocompromised hosts in Infectious Disease in
Emergency Medicine, Lippincott, 1992. pp 367-385.
10
Letters
1. Serody JS, Fever in Immunocompromised Patients in the New England Journal of
Medicine, 342(3): 217-18, 2000.
2. Peppercorn A, Serody JS, Cairns BA. Cytomegalovirus reactivation in critically ill
immunocompetent patients. JAMA letter 300(20): 2367-2368, 2008.
Abstracts:
1. Vincent B, Orellana C, Buntzman A, Scott E, Clarke S, Prins J, Serody J. Pacific
Biosciences sequencing of immunoglobulin receptor repertoires. Nature
Immunology/Hudson Alpha Conference, October 2012.
2. Allen JL, Wooten J, Fore M. Bhuiya NS, Armistead P. Coghill JM, Gabriel D, Roerhrs PA,
Sharf A, Irons RN, Hoffert T, Richards K, Shea TC, Baldwin AB, Serody J, Sarantopoulos
S. B cells from patients with chronic GVHD signal via the AKT-driven survival and
metabolic fitness pathway. Biology of Blood and Marrow Transplantation. 18(2): S207S208, 2012.
3. Walko C, Ivanova A, Whitley J, Rao K, Gabriel D, Serody J, Comeau T, Coghill J,
Armistead P, Sarantopoulos S, Wood W, Shea TC. Beneficial effect of high-dose IV
busulfan delivered by prolonged continuous infusion on relapse rate and overall survival in
matched related and unrelated allogeneic transplant patients with hematologic
malignancies. Biology of Blood and Marrow Transplantation. 18(2): S218-S218, 2012.
4. Lin, KL, West ML, Jones S, Bear J, Serody JS.In vivo assessment of T effector, T
regulatory cell, dendritic cell interaction in lymphoid tissue using intravital imaging during
acute GVHD. Oral session, American Society of Hematology 2011.
5. Fulton, LM, Coghill JM, West ML, Foger N, Serody JS. Impaired donor T cell egress from
recipient lymphoid organs profoundly leads to attenuated acute graft-versus-host disease.
American Society of Hematology 2011.
6. Van Deventer HW, Hoffert T, West ML, Wu QP, Serody JS. Bone marrow stromal cells
inhibit apoptosis of chronic lymphocytic leukemia cells by expressing erythroid
differentiation regulatory 1. American Society of Hematology 118 (21): 769.
7. Shea TC, Waldo C, Inavova, A, Whitley J, Rao K, Gabriel DA, Comeau, T, Coghill H,
Armistead P, Sarantopoulos S, Wood WA, Serody J. Beneficial effect of escalated doses
of busulfan delivered by targeted pharmacokinetics and prolonged continuous infusion on
relapse free and overall survival in matched related and unrelated allogeneic transplant
patients with hematologic malignancies. American Society of Hematology 118(21); 845846, 2011.
8. Fitzhugh DJ, McGinnis MW, Timoshchenko R, Linninger R, Demore N, Serody J, Tarrant
TK. G protein coupled receptor kinase 3 negatively regulates CXCL12/CXCR4 signaling
and tumor migration in breast cancer. Journal of Allergy and Clinical Immunology 127(2):
Pages AB230 2011.
9. Wood WA, Whitley J, Goyal RK, Brown P, Sharf A, Irons RN, Rao K, Essenmacher AN,
Serody J, Coghill J, Armistead PM, Sarantopoulos S, Gabriel DA, Shea TC. Effectiveness
and potential strategies to improve outcomes following chemomobilization with etoposide
11
plus g-CSF in patients undergoing autologous stem cell transplantation for lymphoma.
American Society of Hematology. 118(21): 913-914, 2011.
10. Coghill JM, West ML, Cook DN, Serody JS. The absence of CC-chemokine receptor 8 on
donor regulatory T cells impairs their ability to prevent lethal GVHD. Abstract number III522, American Society of Hematology 2010.
11. Fulton, LM, Carlson MJ, Coghill J, West ML, Panoskaltsisi-Mortari, A, Blazar BR,
Littman D, Serody JS. Attentuated acute graft-versus-host disease following allogeneic
stem cell transplantation in the absence of RORt. Abstract number III-521, American
Society of Hematology 2010.
12. Wooten J, Nazmim BS, Richards K, Sharf A, Antin JH, Soiffer RJ, Ritz R, Shea TC,
Serody J, Baldwin Jr AS, Sarantopoulos S. B cells are primed for survival by BAFF-driven
BIm degradation in chronic graft-versus-host disease patients. Oral session abstract number
110A, American Society of Hematology 2010.
13. Highfill, SL, Rodriguez P, Zhou Q, Goetz CA, Veenstra R, Taylor PA, MortariPanoskaltsis, A, Serody J, Munn D, Tolar J, Ochoa AC, Blazar BR. Bone marrow
myeloid-derived suppressor cells inhibit graft-versus-host disease via an arginase-1
dependant mechanism that is upregulated by IL-13 (oral session abstract 1098, American
Society of Hematology 2010.
14. Voorhees PM, Gasparetto C, Richards KL, Garcia R, Strader JS, Ferraro M, MacLean J,
Winans D, Moore DT, Dodd A, Foster MC, Gabrield DA, Shea TC, Serody J, Van
Deventer HW, Rizvi S, Orlowski RZ, Hurd DD. Vorinostat in combination with pegylated
liposomal doxorubicin and bortezomib for patients with relapsed/refractory multiple
myeloma: Results of a Phase I study. American Society of Hematology 114(22): 129-130,
2009 (oral presentation).
15. Peppercorn, A, Wenink E, Serody J, Cairns B, Jones S, McKinnon K, Barnes C, Maile R,
Ashton F, Schmitz J, Mach, S. A Longitudinal Study of Cytomegalovirus Reactivation and
T Cell Immunity Following Burn Injury: Preliminary Analysis. Infectious Disease Society
of America. September 2009, Oral session.
16. Carlson MJ, Coghill JM, West ML, Mortari AP, Blazar BR, Serody JS. CCR1 is required
for Treg-mediated protection from lethal acute graft-versus-host disease. Abstract 1337,
poster session. American Society of Hematology 2009
17. Voorhees PM, Gasparetto C, Richards K, Garcia R, Strader J, Ferraro M, MacLean J,
Winans D, Moore DT, Dodd A, Moster M, Gabriel DA, Shea TC, Serody JS, van Deventer
HW, Rizvi S, Orlowski RZ, Hurd DD. Vorinostat in combination with pegylated liposomal
doxorubicin and bortezomib for patients with relapsed/refractory multiple myeloma:
Results of a Phase I study. Abstract #306 oral session. American Society of Hematology
2009.
18. Tran TN, Ray GT, Saddler P, Trigg M, Hayes N, Li Y, Rizzieri DA, Stein A, Weber D,
Serody J, Raasch R, Habel L. Immunocompromised status of pateints with hematologic
and soldi tumor malignancies: Construction of a practical algorithm. American Society of
Hematology 114(22): 980, 2009.
19. Mango RL, van Deventer HW, Wu, QP, Serody JS. Pulmonary stromal cells expressing CC
chemokine receptor 5 promote metastasis via erythroid differentiation regulatory 1.
Abstract 3601 poster session, American Society of Hematology 2009.
20. Foster MC, Christensen R, Egan J, Whitley J, Chiu WK, Serody J, Gabriel D, Ivanova A,
Dunphy CH, Shea TC. Prognostic impact of bone marrow CD138 immunohistochemistry
12
prior to autologous stem cell transplant for multiple myeloma. American Society of
Clinical Oncology, 27(15): S8600, 2009.
21. Wood WA, Deal AM, Moore DT, Whitley J, Sharf A, Serody JS, Gabriel DA, Shea TC.
Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI)
in predicting outcomes for adolescents and youing adults (AYAs) with hematologic
malignancies undergoing allogeneic stm cell transplant. American Society of Clinical
Oncology, 27(15): S7034, 2009.
22. Blazar BR, Miller JS, Panoskaltsis-Mortari A, Weigel B, Krige AM, Sharpe AH, Murphy
WJ, Serody J, Hemmi H, Akira S, Levy RB, Taylor PA, In vivo effects of Toll-like
receptor signaling on T-cell responses for GVHD and GVL. Journal of Pediatric
Hematology Oncology, 31(4): 240-241, 2009 (oral presentation).
23. Wood WA, Walko CM, Rao KV, Whitley J, Moore DT, Gabriel DA, Serody JS, Coghill
JM, Shea TC. Identificaiton of an AUC of 7603 uMol x min/hour per day x 4 days as the
maximum tolerated dose of IV continuous infusion busulfan with fixed dose fludarabine in
a pharmacokinetically-based dose phase I study in patients with hematologic malignancies
undergoing allogeneic stem cell transplantation, American Society of Bone Marrow
Transplantation, 15(2): S99, 2009.
24. Coghill, JM, Hogan KN, Serody JS. The absence of CCR7 on donor T cells leads to
attenuated graft-versus-host disease (GVHD) with a preserved graft-versus-leukemia (GvL)
effect. Blood, 112:810, 2008 (oral presentation).
25. Serody J, Wysocki CA, Moran TP. Recruitment of donor T cells to secondary lymphoid
tissue is enhanced by conditioning therapy and donor T cells/marrow. Blood poster session
112, 3506.
26. Peppercorn A, Maile R, Barnes C, Serody J, Frelinger JA, Cairns BA. Viral reactivation
and disease: A potentially important contributor to morbidity and mortality following
severe burn injury. Southern Medical Journal 1900(12), S17, 2007.
27. Shea TC, Serody JS, Gabriel D, Comeau T, Ivanova A, Moore D, Irons R, Whitley J,
Sharf A, Dunphy C, Brecher M. Low incidence of GVHD and treatment-related morbidity
with intermediate doses of continuous infusion IV busulfan and daily fludarabine with
individualized doses of alemtuzumab for matched related and unrelated transplant patients
with high-risk hematologic malignancies. America Society of Hematology, 110(11): 310B,
2007.
28. Carlson MJ, Serody JS. TH17 cells mediate extensive skin pathology in acute GVHD.
American Society of Hematology, #356, 2007.
29. Coghill JM, Seidel H, Serody JS. Absence of CCR4 enhances the function nof expanded
regulatory T cells. American Society of Hematology #362, 2007.
30. Carlson MJ, Seidel HE, Serody JS. CD62L is not critical for T regulatory cell mediated
protection from lethal acute GVHD. American Society of Hematolgoy #368, 2007.
31. Buie L, Rao KV, Epstein S, Shea TC, Comeau T, Gabriel DA, Irons R, Eron B, Serody J.
Symptomatic imiprovement following intravesicular didofovir for the management of BK
virus associated cystitis. American Society of Hematology, 110(11): 883A, 2007.
32. Raetzsch CF, Brooks NL, Moore KS, Marshall T, Klebanov S, Watson LJ, Trent CM,
Kupper LL, Akira S, Bear JE, Serody JS, Swenberg JA, Combs TP. Chronic TLR4 and
MYd88 activation causes hepatic insulin resistance by impairing PI3K inhibition of NFkappa B. American Diabetes Association Meeting, 56(Supp1): A348, 2007.
33. Shea TC, Walko C, Serody J, Gabriel D, Comeau T, Rao K, Ivanova A, Sharf A, Krasnov
13
C, Coghill J, Whitley J, Lindley C. Safety and efficacy of high-dose busulfan by 90-hour
continuous infusion in hematologic malignancy patients undergoing allogeneic stem cell
transplants. American Society of Bone Marrow Transplanation, 13(2): 99-100, 2007.
34. Beaven AW, Comeau TC, Sharf A, Moore DT, Serody J, Shea TC, Gabriel DA.
Mitoxantrone and melphalan as conditioning regimen for autologous stem cell transplant
for multiple myeloma. American Society of Hematology #174-III, 2006.
35. Taylor PA, Ehhardt MJ, Roforth MM, Swedin JM Panoslaltsis-Mortari A, Serody JS,
Blazar BR. Mechanisms responsible for and strategies to overcome bone marrow rejection
in allosensitized recpients. American Society of Hematology, #441-III, 2006.
36. Blazar BR, Panoskaltsis-Mortari A, Krieg AM, Kaemmi H, Akira S, Serody J, Murphy WJ,
Taylor PA, In vivo CpG administration accelerates Graft-versus-host disease lethality ty
Toll-like receptor 9 ligation of host antigen-presenting cells and promotes allogeneic bone
marrow rejection by TLR9 ligation of donor APCs. Oral Session, American Society of
Hematology, 2006.
37. Taylor PA, Ehrhardt, MJ, Panoskaltsis-Mortari, A, Serody JS, Brinkmann V, Blazar BR.
FTY720 inhibits graft-versus-host disease and allogneeic bone marrow graft rejection
independent of effect on T cell egress from lymphoid tissue: Oral session. American
Society of Hematology 2006.
38. DuPont JA, Euliss LE, Orlowski RZ, Serody J, Hahn KM, Welch CM, Small GW, Ferer I,
DeSimone JM. COLL 43-applying imprint lithography (PRINT) for the generation of hapespecific, targeted nanocarriers in medicine. American Chemical Society, 232(43-COLL),
2006.
39. Euliss LE, DuPont JA, Welch CM, Pisano E, Lin WL, Small GW, Orloski RZ, Serody J,
Hahn KM, DeSimone JM. COLL-219-utilizing the emerging imprint lithography technique
(PRINT) for the fabrication of shape-specific organic naonparticles for applications in
nanomedicine, American Chemical Society, 232(219-COLL), 2006.
40. Lambeth C, McKinnon K, Serody J, de Dilva A. Effect of DENV3 infection of primary
human dendritic cells, American Society of Tropical Medicine and Hygiene, 73(6); S240,
2005.
41. Beaven A, Shea TC, Gabriel DA, Comeau T, Irons R, Moore DT, Lin L, Sharf A, Krasnov
C, Becher ME, Serody J. Long term effects on GVHD and survival following the use of GCSF stimulated bone marrow veruss G-CSF mobilized peripheral blood stem cells in HLA
matched sibling transplant. American Society of Hematology S5385, 2005.
42. Shea TC, Walko C, Gabriel D, Serody J, Comeau T, Irons R, Gilman A, Krasnov C, Sharf
A, Linley C. Clinical and pharmacokinetic results of a four-day continuous infusion of fulldose busulfan in patients undergoing matched related or unrelated stem cell transplant.
American Society of Hematology, S1752, 2005.
43. Walko CM, Lindley CM, Collins J, Krasnov C, Harvey RD, Gabriel DA, Serody J,
Comeau T, Shea TC. 90 hour continuous intravenous busulfan infusion: PK and test dose
predictability in allogeneic bone marrow transplantation patients. American Society of
Clinical Oncology, 23(16): 598S, 2005.
44. Harvey RD, Shea T, Walko C, Krasnow C, Patel L, Serody J, Gabriel D, Comeau T,
Lindley C. Intravenous busulfan test dose clearance comparison with first and thirteenth
dose systemic exposure in allogeneic bone marrow transplantation patients. American
Society of Clinical Oncology, 23(16): 599S, 2005.
45. Van Deventer HW, O’Connor W, Brickey W, Ting J, Serody J. Chemokine receptor 5
14
promotes pulmonary metastasis, Federation of the American Society of Experimental
Biology, 19(4): A942, 2005.
46. Shea TC, Serody J, Gabriel D, Comeau T, Morris D, Irons R, Harvey D, Sharf A, Krasnov
C, Dunphy D, Bandrenko N, Brecher M. High relapse rate following alemtuzamab use in
allogeneic transplants for myeloid hematologic malignancies. American Society of Bone
Marrow Transplantation, 11(2): S28-29, 2005.
47. Taylor P, Panoskaltsis-Mortari A, Noelle R, Rudensky A, Serody J, Blazar B. Visualizing
allogeneic bone marrow graft rejection, American Society of Hematology, Abstract 43,
2004 (oral presentation).
48. Taylor P, Panoskaltsis-Mortari A, Freeman G, Sharpe A, Noelle R, Rudensky A, Mak T,
Serody J, Blazar B. The ICOS:ICOSL costimulatory pathway plays an important role in
GVHD and bone marrow graft rejection. American Society of Hematology, Abstract 591,
2004.
49. O’Shaughnessy ML, Vogtenhuber C, Serody JS, Sitcheran R, Baldwin AS, Dang L, Jaffee
B, Blazar BR. Ex vivo blockade of NF-kappa B signaling in alloreative T celsl prevents
murine GVHD. American Society of Hematology, A3058, 2004.
50. Comeau, T, Shea, TC, Gabriel D, Morris, D, Irons, R, Harvey, D, Sharf, A, Krasnov, C,
Dunphy, C, Benderenko, Brecher, M, Serody JS. BK viruria in patients undergoing
allogeneic hematopoietic stem cell transplantation: Increased incidence in patients
receiving alemtuzumab as conditioning therapy and lack of efficacy of cidofovir. ASH,
2004 Poster session--#3160.
51. Blazar BR, Panoskaltsis-Mortari A, Levine BB, June CH, Lucas PP, Gress R, Serody JS,
Taylor PA. The role of CD4+/CD25+ T regulatory cells in allogeneic bone marrow. Blood
cells, molecules and diseases, 33(3): 196, 2004.
52. Moran, TP, Collier M, Davis NL, McKinnon KP, Serody JS, Johnston RE. Transduction of
human and murine dendritic cells with Venezuelan equine encephalitis virus replicon
particles: A potential method for inducing tumor immunity. American Society of Virology
Poster Session #9, Abstract 14, 2004
53. Van Deventer HW, Ng-Cashin J, Kuhns, JJ, Ting YPJ, Serody, JS. Differences in the
Growth of Local vs Metastatic Melanoma After T Regulatory Cell Depletion. American
Association of Immunology, 2004
54. Wysocki, C, Burkett, S, Chwastiak, K, Taylor, P, Blazar, BR, Serody JS. CCR5 Expression
on CD4+CD25+ Regulatory T Cells Plays a Critical Role in Their Ability To Prevent
GVHD. American Society of Hematology, 517, 2003 (oral presentation).
55. Mortari, AP, Price, AP, Hermanson, JR, Taras, E, Lees, C, Serody JS, Blazar, BR. In Vivo
Imaging of Graft-versus-Host-Disease (GVHD) in Mice. American Society of
Hematology,513, 2003 (oral presentation).
56. Comeau, T, Serody J, Gabriel DA, Wiley, J, Kirby, S, Iron, R, Hill, D, Tuttle, R, Wilson,
C, Kok, B, Bandarenko, N, Brecher, ME, Shea, TC. Combined Infusion of Peripheral
Blood Stem Cells (PBSC) Bone Marrow (BM) in Poorly Mobilizing Patients Undergoing
High-Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT). American
Society of Hematology, 988A, 2003.
57. O’Shaughnessy MJ, Vogtenhuber C, Serody J, Sitcheran R, Baldwin A, Dang L, Adams J.
Blazar BR. Ex vivo blockade of NF-kappa B signaling in alloreactive T cells prevents
murine GVHD. Federation of the American Society of Experimental Biology, 17(7): C60,
2003.
15
58. Moran, T, Long, B, Collier M, Davis, NL, McKinnon, KP, Ng-Cashin J, Johnston, R,
Tisch, R, and Serody JS. In vivo and in vitro activities of Venezuelan equine encephalitis
viral replicons encoding HER-2/neu in the prevention and treatment of breast cancer. 11th
SPORE Meeting, Baltimore MD, #116, 2003.
59. O’Shaughnessy, MJ, Vogtenhuber C, Serody JS, Sitcheran, R, Baldwin A, Dang, L,
Adams, J, Blazar, BR. Ex vivo Blockade of NF-(B Signaling in Alloreactive T cells
Prevents Murine Graft-versus-host Disease (GVHD). American Association of
Immunology. Transplantation Immunology 1, 37.9, Denver CO. 2003.
60. Bushman JE, Mauriello CT, Walton WG, McKinnon KP, Serody JS, Kirby SL. Effects of
a truncated erythropoietin receptor (tEpoR) transgene on proliferation and function of
dendritic cells derived from murine bone marrow. American Society of Hematology,
100(11): 404A, 2002.
61. Wysocki CA, Burkett SB, Kirby SL, McKinnon K, Craven R, Blazar BR, Serody JS.
Absence of CCR5 on donor T cell accelerates GVHD. American Society of Hematology,
A5200, 2002.
62. Gabriel DA, Shea T, Serody J, Kirby S, Bigelow S, Kanamond L, Moore DT, Irons R.
Cytoprotection by amifostine during autologous stem cell transplant for advanced
refractory hematologic malignancies. American Society of Hematology, 415A, 2002.
63. Engelhardt B, Serody J, Gabriel D, Kirby S, Wily J, Bigelow S, Harvey D, Moore D,
Gilligan P, Banderenko N, Shea T. Use of prophylactic ganciclovir and CMV antigen
screening in allogeneic transplant patients receiving high-dose steroids. American Society
of Hematology, A5342, 2002.
64. Shea T, Gabriel D, Kirby S, Serody J, Tsuie A, Capel E, Bigelow S, Booker J, Brecher M,
Banderenko N, Wiley J. Non-myeloablative transplants using cyclophosphamide and
fludarabine with g-CSF stimulated bone marrow. American Society of Hematology,
A5304, 2001.
65. Panoskaltsis-Mortari A, Hermanson JR, Serody JS, Blazar BR. Acceleration of idiopathic
pneumonia syndrome in the absence of door macrophage inflammatory protein-1 alpha
following allogeneic bone marrow transplant in mice. Federtion of the American Society of
Experimental Biology, 15(4): A359, 2001.
66. Dees EC, McKinon K, Myers M, Sparks SD, Chwastiak K, Collichio F, vanDeventer HW,
Carey LA, Brecher ME, Graham M, Serody JS. Phase I clinical trial of HER2 peptidepulsed autologous dendritic cells in patients with metastatic breast cancer, Breast Cancer
Research and Treatment, 59(3): 311, 2001.
67. Gabriel DA, Serody JS, Kirby S, Capel E, Bigelow S, Moore D, Shea TC. Efficacy of
peripheral blood stem cell or mobilized marrow transplant in the treatment of refractory
multiple myeloma. American Society of Hematology, A5283, 2000.
68. Shea TC, Wiley J, Serody J, Gabriel D, Powell E, Bigelow S, Schultz S, Brecher M,
Bentley S, Lin Y, Schell M. Fixed dose G-CSF post autologous peripheral blood stem cell
transplantation permits utilization of lower doses of growth factor without compromising
engraftment. American Society of Hematology, A525, 1998 (oral presentation).
69. Gabriel DA, Melton LG, Thompson CM, Shea TC, Serody JS, Wiley JM, Powell E,
Bigelow S. Transient impact of stem cell infusion on platelet function. American Society of
Hematology, A4388, 1998.
70. Serody JS, Cook D, Reap E, Cohen P, Freligner JA, Shea TC. Blockade of T lymphocyte
production of the chemokine MIP-1 alpha decreases the severity and time to onset of
16
chronic GVHD across a clas I but not class II MHC barrier. American Society of
Hematology 90(10): 909, 1997.
71. Shea T, Wiley J, Serody J, Gabriel D, Powell E, Scott C, Banderenko N, Brecher M,
Bentley S. CD-34 mobilization with intermediate dose cyclophosphamide, paclitaxel and
G-CSF. American Society of Hematology, 90(1): 4260, 1997.
72. Wiley, J, Shea T, Powell E, Serody J, Gabriel D, Sailer S, Killian D, Bentley S, Brecher
M. A phase I-II study of cyclophosphamide, VP-16, carboplatin and total body irradiation
with autologous stem cell transplantation for acute leukemia. American Society of
Hematology, 88(1): 3702, 1997.
73. Serody J, Brecher M, Shea T, Frelinger J. Production of allogeneic leukemia-specific
CD4+ lymphocytes in vitro. American Society of Hematology, 86(10): 617, 1995.
74. Gray F, Shea T, Wiley J, Serody J, Powell E, LaChapelle J, Pope B, Sailer S, Bentley S,
Brecher M. Phase I/II results of cyclophosphamide, VP-16, carboplatin and total body
irradiation with autologous stem cell transplantation for hematologic malignancies.
American Society of Hematology, 86(10): 3778, 1995.
75. Serody J, Wiley JM, Gabriel DA, Powell E, Scott C, Lawrence P, Bentley SA, Brecher
ME, Folds F and Shea TC. Comparison of the use of G-CSF stimulated peripheral blood
stem cells or G-CSF-stimulated Bone Marrow in six antigen matched allogeneic
transplantation. Proceedings of ASCO, 1997.
76. Serody JS, Berry MM, Weber DJ, Schell MJ, O'Brien SM, Gabriel DA, Wiley JM,
Gilligan PH and Shea TC. Utility of blood cultures during febrile leukopenia in bone
marrow transplant recipients. Proceedings of ASCO, 16:413a, number 1474, 1997.
77. Berrey MM, Weber DJ, Schell M, Powell E, Gilligan P, Gabriel DA, Wiley JM, Shea TC,
Serody JS. Utility of blood cultures in bone marrow transplant recipients with leukopenia.
Proceedings of ASCO oral presentation 1995.
78. Shea T, Wiley J, Serody J, Mason J, Powell E, Van Le L and Fowler W. High-dose
chemotherapy with melphalan, VP-16, carboplatin, thiotepa, and mitoxantrone in patients
with advanced epithelial ovarian cancer. Proc ASCO 14:462, 1995. (Abstract 1492).
79. Shea T, Graham M, Bernard S, Steagall, Wiley J, Serody J, Johnston C, Brecher M,
Bentley S, Van Le L and Fowler W. Multiple cycles of high dose paclitaxel plus
excalating doses of carboplatin with G-CSF (filgrastim) and peripheral blood stem cell
(PBSC) support. Proc ASCO 14:478, 1995. (Abstract 1555).
80. Shea T, Wiley J, Sailer S, Powell P, Serody J, Mason J, Storniolo AM, Seagren S, Bentley
S and Brecher M. A phase I study of cyclophosphamide, VP-16, carboplatin, and total
body irradiation with autologous stem cell transplantation for hematologic tumors. J. of
Cellular Biochemistry. Abstract Supplement 18B(83), 1994
81. Serody JS, Charniga LM and Cohen MS. Identification of a putative lacoferrin receptor
on the monocytoid cell line U937. Clinical Research 39:1990.
82. Serody JS, Weber RD, Hassett DJ, Charniga LM, Yount PL and Cohen MS. Physiologic
response of U937 cells to redox stress: Demonstration of novel heat shock proteins.
Clinical Research 38:394A, 1990.
Invited Abstracts:
Blazar, BR, Panoskaltsis-Mortari, Serody JS, Lees, CJ, Erhhardt MJ, Swedin JM, Murphy WJ,
Noelle RJ, Levine BL, June CH, Sagaguchi S, Taylor P. The role of CD4+CD25+ T regulatory
17
(Treg) cells in allogeneic bone marrow transplantation. (BMT). Keystone Symposia on
regulatory T cells, Banff Alberta, 2003.
Dees EC, McKinnon K, Myers M, Sparks S, Chwastiak K, Collichio F, vanDeventer H, Carey L,
Brecher ME, Graham M, Serody JS. Phase I clinical trial of HER2 peptide-pulsed autologous
dendritic cells in patients with metastatic breast cancer (MBC). Oral Presentation at the 9th
Annual SPORE Meeting, 2001.
Licensure:
Board Certified Hematology 1996/recertified 2007
Board Certified Internal Medicine 1989
Medical license North Carolina 1987
Membership
Professional Societies:
American Society for the Advancement of Science
American Society of Bone Marrow Transplantation
American Society of Clinical Oncology
American Society of Hematology
American Association of Immunology
Infectious Disease Society of America
International Society for the Biological Therapy of Cancer
Southern Bone Marrow Transplant Society
Professional Service (Consultant):
Pharmacia Incorporated on a project evaluating the use of glutamine to enhance TPN in bone
marrow transplant patients
CellPro, Incorporated on a protocol to evaluate the use of the CD34+ selection system in patients
with lymphoma
Merck, Sharpe & Dohme - Monotherapy for neutropenia
Data Safety Monitoring Board for Glaxo Wellcome evaluation hematological toxicity of antidepressant
Management of fever and neutropenia Elan Pharmaceuticals
Evaluation of Patient Populations to administer Oka/Merck Varicella Zoster Vaccine—Merck
Data Safety Monitoring Board for Immtech Pharmaceutical anti-infective studies
18
Consultant for pharmacological therapy for inflammatory diseases TheraLogics
Consultant for Approaches to Diminish Acute/Chronic GvHD: Novartis
Editorial Positions:
Editorial Board: Journal of Clinical Oncology 2009-2012
Editorial Board: Blood 2011-present
Associate Guest Editor: Blood 2012
Abstract Section Head Reviewer
Infectious Disease Society of America
Immunocompromised Host Section 1996
Abstract Reviewer
Tumor Immunotherapy ASH 2008
Ad-Hoc Journal Reviewer:
American Journal of Hematology
American Journal of Transplantation
Biology of Blood and Marrow Transplantation
Blood
Bone Marrow Transplantation
Cancer Research
Clinical and Laboratory Haematology
Clinical Cancer Research
Journal of Clinical Investigation
Journal of Clinical Oncology
Journal of Hepatology
Journal of Immunology
Journal of Immunotherapy
Journal of Virology
Leukemia and Lymphoma
Melanoma Research
Nature Medicine
Proceedings of the National Academy of Sciences USA
Science Translational Medicine
Stem Cells
Vaccine
Previous Grants Funded:
UCRF Grant: Multimodality Therapy for Breast Cancer: 2009-2011
STTR Phase 1 and Phase 2 Grants: Blockade of NF-B for the Prevention/Treatment GvHD
2007-2011
R01: Treg Migration in GvHD: 2004-2009
R01: Mechanisms of T cell Trafficking in GVHD 2003-2008
ARRA Supplement to Treg Migration in GVHD Grant: 2010
R56: Treg Migration in GVHD: 2011
R21: Combined Modality Therapy for the Treatment of Patients with Metastatic Breast Cancer
who Express HLA-A0201
19
Lineberger Clinical Cancer Center Small Grant Award 2003-04
R21: Immunotherapy for the Treatment of Metastatic Breast Cancer 2000-02
KO8 Award National Cancer Institute 1996-2001
Lineberger Clinical Cancer Center Small Grant Award, 1995-96
National Research Service Award 1991-1992
Teaching Experience:
2011
Co-course Director Microbiology 212 Seminar on T cell fate determination
2010-current Lecture on Why Immunology is Important for Clinical Medicine to first year
medical students
2008-current Lecture on Hodgkin’s Lymphoma to Hematology/Oncology Fellows
2006-2011
Lecture on Transplantation Immunology to first year medical students
2005-current Lecture to Hematology/Oncology Fellows concerning tumor immunology
2000-current Lecturer for Hematology/Oncology Fellows Infections in Cancer Patients
1999-2011
Lecture on Tumor Immunology in First Year Medical School Immunology Class
2003
Course Director Microbiology 212 Seminar in Innate Immunity
2000-2002
Lecturer for Hematology/Oncology Fellows Tumor Immunology
1999
Course Director Microbiology 212 Seminar in Dendritic Cell Biology
1996-2004
Lecturer Bimonthly Fever and Neutropenia Treatment to the Housestaff and
Students
1994--1997 Lecturer Nutrition 221: Tumor Immunology
1996 - 2004 Lecturer Cancer Pathology 213 Tumor Immunology for Graduate Students
1996 1998 Medical School Lecture T cell Activation and GVHD
1995 – 1996 Laboratory Instructor, Hematology
1995 - 2002 Laboratory Instructor for Microbiology and Immunology
1993 - 1994 Clinical Pathology Conference UNC Chapel Hill
Grand Rounds and Continuing Medical Education Lectures
2012: Transplantation Immunology Grand Rounds: “Intravital Imaging and Regulatory T cell
Function”, Medical College of Wisconsin, Milwaukee, WI
2012: Transplantation Immunology Grand Rounds MD Anderson Cancer Center: “Mechanisms
of action of regulatory T cells using intravital imaging.”
2012: Management of Patients with Hodgkin’s Lymphoma: Medical Grand Rounds, New
Hanover Medical Center, Wilmington NC
2012: Th17 Cells and GVHD Symposium at American Society for Bone Marrow
Transplantation Meeting San Diego CA: “Th17/Th22 Cells in Acute GvHD; Lead Actors
or Bit Players.”
2012 Oncology Grand Rounds Wake Forest Baptist Hospital: T cell subsets and GVHD
2011 American Association of Immunology Meeting Presidential Symposium: Stem Cell
Transplantation from the miraculous to the mundane
2010 UAB Departmental Grand Rounds: Targeting lymphoid migration to Prevent GvHD:
2009: Transplant Immunology Seminar Series MD Anderson Cancer Center: Chemkines and
GVHD
2009 Immunology Department Seminar Series: Duke University School of Medicine
2009 Oncology Seminar Series: East Carolina School of Medicine
2009 Pathology Grand Rounds UNC School of Medicine
20
2008 UAB Cancer Center: Migration is Critical for the Good and the Bad
2008 Cancer Center Grand Rounds City of Hope Medical Center T cell Subsets Migration and
GVHD
2005 Grand Rounds Medical University of South Carolina:--Migration Important in GVHD
and Tumor Vaccination
2005: Oncology Grand Rounds Lineberger Comprehensive Cancer Center: Migration and
GVHD and Tumor Vaccination
2004 Duke Hematology/Oncology Symposia Treatment of Fungal Infections in Transplant
Patients
2003 Medical School Research Symposium 2003 Vaccine Therapy for Breast Cancer: From
Bench to Patients and Back
2003 Grand Rounds New Hanover Medical Center Tumor Immunology
2003 BMT Grand Rounds DUMC Fungal Infections in BMT Patients
2001 BMT Grand Rounds Duke University Hospital Infection in BMT Patients
2001 BMT Grand Rounds University of Minnesota Chemokines in Transplantation
2001 Grand Rounds at CMC Charlotte NC Update on New Antifungal Drugs
1999 Grand Rounds at CMC Charlotte NC; Management of Febrile Cancer Patients
1998 BMT Grand Rounds University of Colorado Chemokines and GVHD
1998 Grand Rounds: University of Tennessee at Knoxville. Update on Fever and Neutropenia
1998 AHEC:Lecture on Fever and Neutropenia. Carolinas Medical Center
1998 AHEC:Lecture on Fever and Neutropenia. Rex Medical Center
1995 AHEC:Lecture on bone marrow transplantation for CML Wake Medical Center
Postdoctoral Fellows Trained in Serody Laboratory
*Hank Van Deventer MD
Jennifer Kuhns PhD
Judith Ng-Cashin MD
John Powderly MD
Heather Shearer MD
James Coghill MD
Michael Carlson PhD
Laura Ott PhD
Current Postdoctoral Fellows in the Laboratory:
Kaifeng Lin PhD
Benjamin Vincent MD
Grace Kim MD
Malini Boomiasami PhD
Graduate Student Laboratory Work:
Supervisor for Julia Gambone Immunology Rotation 2010
Supervisor for Meghan Free Immunology Rotation 2009
Supervisor for Ginny Hench Immunology Rotation 2003
Supervisor for Kristopher Curtis Immunology Rotation 1999
Supervisor for Karen Albritton MD clinical research rotation 1997
21
Supervisor for M Michelle Berrey MD on a clinical research rotation September 1995
Basic Science Teaching
Supervisor for LeShara Fulton 2009 IBMS Program
Supervisor for Nick Taylor 2010 MD PhD Program
Supervisor for Trisha Dant 2012
*co-trained with Jenny Ting PhD
Students Completed Training:
Timothy Moran MD PhD Program; PhD Completed 2006
Christian Wysocki MD PhD Program: PhD Completed 2005
Joseph Burgents PhD IBMS Program: PhD Completed 2010
Robert Mango PhD in the MD PhD program Completed 2010
Laura Greene 2005-2006: Left to attend Veterinary School.
Current Graduate Students:
Nick Taylor (MD PhD Program)
LeShara Fulton (HHMI Translational Medicine Program)
Trisha Dant
Committee Memberships Graduate School:
Eileen McMahon
Jeffrey MacKeigan
Brian Long
Shannon Pop
Cassandra Lambeth
Reed Shabman
Kelly Roney
Meredith Burgents (DDS Program)
Ginnie Hench
Sarah Stein
Eda Holl
Alaina Garland
Mark Johnson
Reid Roberts (Chair)
Amy Beres (External Reader Medical College of Wisconsin PhD program)
Microbiology/Immunology Preliminary Committees:
Reid Roberts
Mark Johnson
Eric Meissner
Jin Hyang Kim
Undergraduate Students Rotating Through Laboratory:
Janelle Vargas
22
Ivana Ferrer
Robin Craven
Richard Park
Bureaucratic Duties:
-Director of Oncology Grand Rounds Lineberger Comprehensive Cancer Center
-Member Educational Committee for the Hematology Oncology Fellowship Program
-Member of the Executive Committee for the Division of Hematology and Oncology University
of North Carolina at Chapel Hill
-Member of the Program Planning Committee Lineberger Comprehensive Cancer Center
-
GRANT INFORMATION
Active
National Institutes of Health (Serody)
7/1/2012-6/30/2017
Direct
$250,000
Targeting CCR7 for the Treatment/Prevention of GvHD
RO1 CA163725
The goals of this work are to evaluate approaches to block T cell migration to prevent/treat
GVHD
National Institutes of Health (Serody)
4/1/2012-3/30/2017
Direct
$186,500
Th1/Th17 cell macrophages interactions in cutaneous GvHD
RO1CA166794
The goals of this work are to investigate the function of Th17 and Th22 cells in acute and
chronic GvHD
Leukemia and Lymphoma Society (Serody)
10/1/2010-9/30/2013
Direct
$178,200
Blocking T cell Effector Function in GVHD
The goals of this work are to evaluate translational approaches to block organ-specific GVHD by
targeting T cells responsible for tissue injury
Susan G.Komen For the Cure (Serody)
7/1/2010-6/30/2013
Direct
$150,000
KG100307
Combined Modality Therapies for the Treatment of Metastatic Breast Cancer
10% effort
The goals of this work are to combine dendritic cell vaccination with vinorelbine and
trastuzumab for the treatment of patients with metastatic breast cancer
National Institutes of Health (Earp)
9/1/2012-8/31/2017
SPORE in Breast Cancer
$220,000
Project 2
Function of the immune infiltrating cells in the biology of claudin-low and basal-like breast
23
cancer
The goals of this project are to evaluate the activity of immune cells in basal-like and claudinlow breast cancer
Breast Cancer Research Foundation (Earp)
7/01/09-6/30/10
Direct
$28,000
Immunotherapy for Breast Cancer
This grant supports a clinical trial involving the use of vaccine therapy with chemotherapy and a
biological response modifier
National Institutes of Health (Earp)
6/1/2004-11/30/2010
Cancer Center Core Support Grant
P30CA016086
This supports Dr. Serody’s role as co-leader of the Immunology program of the Lineberger
Cancer Center and as leader of the malignant hematology program
National Institutes of Health (Key)
4/1/2007-3/30/2012
Research Fellowships in Hematology Oncology
T32HL007149
5% effort (no salary requested)
Dr. Serody directs the malignant hematology research fellowship section for this T32 proposal.
Glaxo Smith Klein (Serody)
7/1/2011-6/30/2013
Direct
$152,000
Immune Assessment Post Vaccination
The goals of this work are to evaluate T cell activity after infectious disease vaccination.
National Institutes of Health (Coghill)
4-1-2012-3-31-2017
K08HL11205
Dr. Serody serves as one of the two co-mentors for Dr. Coghill
National Institutes of Health (Sarantopoulos)
7-12-2011-6-30-2015
K08HL107756
Dr. Serody serves as one of the two co-mentors for Dr. Sarantopoulos
Leukemia and Lymphoma Society (Lin)
Dr. Serody serves as the mentor for Dr. Lin’s fellowship grant.
7-1-2012-6-30-2015
Committee Memberships:
2012-current
2012-current
2009-current
2009-current
2007-current
2003-current
2005-2010
LCCC T32 Fellowship Selection Committee
Core Facilities Advocacy Committee: Clinical Cores
Protocol Office Executive Committee LCCC
Animal Space Use Committee School of Medicine UNC-CH
University Cancer Fund Equipment Committee
Flow Cytometry Committee UNC
Chair Lineberger Cancer Center Translational Research Grant Committee
24
2005-2008
2005-current
2005-current
2004-2007
1995-1998
1996-current
1996-2006
School of Medicine Research Advisory Committee
Division of Hematology and Oncology Educational Committee
Division of Hematology and Oncology Executive Committee
Member of the University of North Carolina Data Safety Monitoring
Board
Lineberger Comprehensive Cancer Center Advisory Committee
Antibiotics and Therapeutics Subcommittee, UNC-Chapel Hill
Pharmacy and Therapeutics Committee, UNC-Chapel Hill
Attending Duties:
Clinical Service six weeks each year on the Clinical Bone Marrow Transplantation Service and
malignant hematology inpatient service
Patents and IND’s
IND number BB#8037 from the FDA for the use of peptide based vaccine therapy for the
treatment of patients with metastatic breast and locally advanced ovarian cancer
25